【摘要】 目的 評價重組人血小板生成素（rhTPO）治療腫瘤化療后血小板減少的療效和安全性。 方法 2008年12月-2009年10月收住惡性腫瘤患者45例，在化療后出現血小板減少，隨機分為A、B組，A組皮下注射rhTPO（15 000 U/d），B組皮下注射白細胞介素-11（1.5 mg/d），動態監測注射后血小板生長情況。 結果 A組血小板計數的最低值明顯高于B組（Plt;0.05）；A組血小板開始恢復時間較B組明顯縮短（Plt;0.01）；血小板恢復至100×109/L以上所需時間A組較B組明顯縮短（Plt;0.05），分別為（6.18±4.20）和（10.46±4.54） d，血小板恢復的最高值兩組差異無統計學意義（Pgt;0.05）；B組有2例患者化療后需要輸入外源性血小板，A組無患者需要輸入血小板；與B組比較，A組較少發生不良反應，患者可以耐受。 結論 重組人血小板生成素是一種治療化療后出現血小板減少的有效方法。【Abstract】 Objective To evaluate the therapeutic effect of recombinant human thrombopoietin (rhTPO) on chemotherapy-induced thrombocytopenia. Methods Forty-five in-patients with malignant tumor from December 2008 to October 2009 who had thrombocytopenia after chemotherapy were randomly divided into A and B groups. The patients in group A underwent the hypodermic injection with rhTPO (15 000 U/d) while in group B with interleukin-11 (1.5 mg/d);the platelet count was checked consecutively. Results Compared with that in group B, the platelet count was obviously higher (Plt;0.01) and the time of declined platelet count beginning to recover was significantly shorter in group A. The time of platelet count increasing to 100×109/L was within (6.18±4.20) days in group B which was significantly shorter than (10.46±4.54) days in group B (Plt;0.05). However, no significant was found between the two groups in the maximal platelet count (Pgt;0.05). Two patients needed platelet transfusion in group B and no one did in group A. Conclusion rhTPO is safe and effective for chemotherapy-induced thrombocytopenia.
